Biocardia regains full compliance with nasdaq listing requirements

Sunnyvale, calif., sept. 18, 2024 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the company has regained full compliance with the nasdaq capital market's listing requirements as required by the hearing panel's (the “panel”) decision on may 13, 2024.

BCDA Ratings Summary

BCDA Quant Ranking